Immix Biopharma
upcoming catalysts ria data pending release more patients current ongoing preclinical studies with | Immix Biopharma
Company
Deck Type
Sector
Industry
Deck date
January 2024
Slide
29 of 64
Similar slides by Immix Biopharma
See diffirences between slides (animation)
Investor Presentation
December 2023
upcoming catalysts ria | Immix Biopharma
Investor Presentation
November 2023
upcoming catalysts ria | Immix Biopharma
Investor Presentation
November 2023
upcoming catalysts ria | Immix Biopharma
Investor Presentation
November 2023
upcoming catalysts ria | Immix Biopharma
Related slides by other companies
Equillium
Investor Presentation
February 2024
driving development towards option decision two data deliverables expected in data deliverables and option decision expected during | Equillium
Disney
Results
May 2023
upcoming theatrical releases title brand date | Disney
Genelux
Investor Presentation
February 2024
primed anti tumor activity primed | Genelux
Nuvalent
Investor Presentation
February 2024
preliminary safety profile favorable and consistent with the highly selective sparing design of phase no no treatment related no aes leading to dose reduction or discontinuation no treatment related dizziness treatment related adverse events in patient all treated patients nausea alt increased ast increased myalgia grade grade grade any grade data as for patients treated by adverse event alt alanine ast aspartate dose limiting including source a toxicity | Nuvalent
Other recent decks by Immix Biopharma
See all presentations (11 decks)
Investor Presentation
March 2024
Investor Presentation
December 2023
Investor Presentation
November 2023
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights